The report details Hanmi Pharm's efforts to achieve economic, social, and environmental value. The report highlights the company's commitment to innovation, open innovation, and global expansion. Specific highlights include the company's continued success in the domestic anti-hypertension market with the ""Amosartan Family"" of drugs, and the release of its first new biologic, ""Rolvedon,"" in the US market. The report also outlines Hanmi Pharm's social contribution activities, including medical aid, support programs for children from multicultural families, and the ""Accompanying Public Bath"" project.
Issuing Company Hanmi Pharm. Co., Ltd.
Report Type Sustainability Report
Report Language EN
Report Filesize 9.9 MB
No. of Pages 131 pages
Reporting periodJanuary 1, 2022-December 31, 2022
Report Edition6
Assurance Provider Korean Standards Association
Reporting Standards GRI Standard; SASB; UNSDGs; others
Materiality Assessmenttrue